Gemcitabine Eliminates Double Minute Chromosomes from Human Ovarian Cancer Cells

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Yu, Lisa ^a   Zhao, Yan ^a   Quan, Chao ^a   Ji, Wei ^a   Zhu, Jing ^a   Huang, Yun ^a   Guan, Rongwei ^a   Sun, Donglin ^a   Jin, Yan ^a   Meng, Xiangning ^a   Zhang, Chunyu ^a   Yu, Yang ^a   Bai, Jing ^a   Sun, Wenjing ^a   Fu, Songbin ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; GAMMA HISTONE H2AX; GEMCITABINE; HYDROXYUREA; NUCLEAR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL INVASION; CELL STRAIN UACC 1598; CHROMATIN; CHROMOSOME LOSS; CHROMOSOME NUMBER; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA CONTENT; DNA DAMAGE; DOUBLE MINUTE CHROMOSOME; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MICRONUCLEUS; OVARY CANCER; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DNA DAMAGE; DNA, NEOPLASM; FEMALE; GENE AMPLIFICATION; HISTONES; HUMANS; HYDROXYUREA; IN SITU HYBRIDIZATION, FLUORESCENCE; MICRONUCLEI, CHROMOSOME-DEFECTIVE; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NUCLEAR PROTEINS; ONCOGENE PROTEINS; OVARIAN NEOPLASMS; PEPTIDE INITIATION FACTORS; REAL-TIME POLYMERASE CHAIN REACTION; RNA-BINDING PROTEINS;

EID: 84882745648     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071988     Document Type: Article

References (57)

1. Abushahin F, Rose PG, (2007) Role of gemcitabine in the treatment of ovarian cancer. Womens Health (Lond Engl) 3: 279-290.
2. Albertson DG, (2006) Gene amplification in cancer. Trends Genet 22: 447-455.
3. Albertson DG, Collins C, McCormick F, Gray JW, (2003) Chromosome aberrations in solid tumors. Nat Genet 34: 369-376.
4. Cowell JK, (1982) Double minutes and homogeneously staining regions: gene amplification in mammalian cells. Annu Rev Genet 16: 21-59.
5. Hamkalo BA, Farnham PJ, Johnston R, Schimke RT, (1985) Ultrastructural features of minute chromosomes in a methotrexate-resistant mouse 3T3 cell line. Proc Natl Acad Sci U S A 82: 1126-1130.
6. VanDevanter DR, Piaskowski VD, Casper JT, Douglass EC, Von Hoff DD, (1990) Ability of circular extrachromosomal DNA molecules to carry amplified MYCN proto-oncogenes in human neuroblastomas in vivo. J Natl Cancer Inst 82: 1815-1821.
7. Rattner JB, Lin CC, (1984) Ultrastructural organization of double minute chromosomes and HSR regions in human colon carcinoma cells. Cytogenet Cell Genet 38: 176-181.
8. Haaf T, Schmid M, (1988) Analysis of double minutes and double minute-like chromatin in human and murine tumor cells using antikinetochore antibodies. Cancer Genet Cytogenet 30: 73-82.
9. Bahr G, Gilbert F, Balaban G, Engler W, (1983) Homogeneously staining regions and double minutes in a human cell line: chromatin organization and DNA content. J Natl Cancer Inst 71: 657-661.
10. Barker PE, (1982) Double minutes in human tumor cells. Cancer Genet Cytogenet 5: 81-94.
11. Shimizu N, (2009) Extrachromosomal double minutes and chromosomal homogeneously staining regions as probes for chromosome research. Cytogenet Genome Res 124: 312-326.
12. Ambros IM, Rumpler S, Luegmayr A, Hattinger CM, Strehl S, et al. (1997) Neuroblastoma cells can actively eliminate supernumerary MYCN gene copies by micronucleus formation-sign of tumour cell revertance? Eur J Cancer 33: 2043-2049.
13. Von Hoff DD, McGill JR, Forseth BJ, Davidson KK, Bradley TP, et al. (1992) Elimination of extrachromosomally amplified MYC genes from human tumor cells reduces their tumorigenicity. Proc Natl Acad Sci U S A 89: 8165-8169.
14. Canute GW, Longo SL, Longo JA, Shetler MM, Coyle TE, et al. (1998) The hydroxyurea-induced loss of double-minute chromosomes containing amplified epidermal growth factor receptor genes reduces the tumorigenicity and growth of human glioblastoma multiforme. Neurosurgery 42: 609-616.
15. Guan XY, Sham JS, Tang TC, Fang Y, Huo KK, et al. (2001) Isolation of a novel candidate oncogene within a frequently amplified region at 3q26 in ovarian cancer. Cancer Res 61: 3806-3809.
16. Guan XY, Fung JM, Ma NF, Lau SH, Tai LS, et al. (2004) Oncogenic role of eIF-5A2 in the development of ovarian cancer. Cancer Res 64: 4197-4200.
17. Eckhardt SG, Dai A, Davidson KK, Forseth BJ, Wahl GM, et al. (1994) Induction of differentiation in HL60 cells by the reduction of extrachromosomally amplified c-myc. Proc Natl Acad Sci U S A 91: 6674-6678.
18. Narath R, Ambros IM, Kowalska A, Bozsaky E, Boukamp P, et al. (2007) Induction of senescence in MYCN amplified neuroblastoma cell lines by hydroxyurea. Genes Chromosomes Cancer 46: 130-142.
19. Bonatti S, Miele M, Menichini P, Ottaggio L, Abbondandolo A, (1989) Preferential loss of chromosomes containing amplified DNA regions in cultured cells. Prog Clin Biol Res 318: 271-276.
20. Shimizu N, Nakamura H, Kadota T, Kitajima K, Oda T, et al. (1994) Loss of amplified c-myc genes in the spontaneously differentiated HL-60 cells. Cancer Res 54: 3561-3567.
21. Shimizu N, Shimura T, Tanaka T, (2000) Selective elimination of acentric double minutes from cancer cells through the extrusion of micronuclei. Mutat Res 448: 81-90.
22. Freeman-Edward J, O'Neill S, Lastowska M, Bown N, (2000) Expulsion of amplified MYCN from neuroblastoma tumor cells. Cancer Genet Cytogenet 116: 87-88.
23. Snapka RM, Varshavsky A, (1983) Loss of unstably amplified dihydrofolate reductase genes from mouse cells is greatly accelerated by hydroxyurea. Proc Natl Acad Sci U S A 80: 7533-7537.
24. Von Hoff DD, Waddelow T, Forseth B, Davidson K, Scott J, et al. (1991) Hydroxyurea accelerates loss of extrachromosomally amplified genes from tumor cells. Cancer Res 51: 6273-6279.
25. Shimizu N, Itoh N, Utiyama H, Wahl GM, (1998) Selective entrapment of extrachromosomally amplified DNA by nuclear budding and micronucleation during S phase. J Cell Biol 140: 1307-1320.
26. Shimizu N, Misaka N, Utani K, (2007) Nonselective DNA damage induced by a replication inhibitor results in the selective elimination of extrachromosomal double minutes from human cancer cells. Genes Chromosomes Cancer 46: 865-874.
27. Shimizu N, (2011) Molecular mechanisms of the origin of micronuclei from extrachromosomal elements. Mutagenesis 26: 119-123.
28. Tanaka T, Shimizu N, (2000) Induced detachment of acentric chromatin from mitotic chromosomes leads to their cytoplasmic localization at G(1) and the micronucleation by lamin reorganization at S phase. J Cell Sci 113 (Pt 4): 697-707.
29. Krakoff IH, Brown NC, Reichard P, (1968) Inhibition of ribonucleoside diphosphate reductase by hydroxyurea. Cancer Res 28: 1559-1565.
30. Yarbro JW, Kennedy BJ, Barnum CP, (1965) Hydroxyurea inhibition of DNA synthesis in ascites tumor. Proc Natl Acad Sci U S A 53: 1033-1035.
31. Young CW, Hodas S, (1964) Hydroxyurea: Inhibitory Effect on DNA Metabolism. Science 146: 1172-1174.
32. Niida H, Shimada M, Murakami H, Nakanishi M, (2010) Mechanisms of dNTP supply that play an essential role in maintaining genome integrity in eukaryotic cells. Cancer Sci 101: 2505-2509.
33. Reynolds C, Obasaju C, Schell MJ, Li X, Zheng Z, et al. (2009) Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 27: 5808-5815.
34. Akita H, Zheng Z, Takeda Y, Kim C, Kittaka N, et al. (2009) Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene 28: 2903-2909.
35. Nakahira S, Nakamori S, Tsujie M, Takahashi Y, Okami J, et al. (2007) Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer 120: 1355-1363.
36. Bepler G, Kusmartseva I, Sharma S, Gautam A, Cantor A, et al. (2006) RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 24: 4731-4737.
37. Bergman AM, Eijk PP, Ruiz van Haperen VW, Smid K, Veerman G, et al. (2005) In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res 65: 9510-9516.
38. Lund B, Kristjansen PE, Hansen HH, (1993) Clinical and preclinical activity of 2′,2′-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev 19: 45-55.
39. Burris HA, (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413.
40. Toschi L, Finocchiaro G, Bartolini S, Gioia V, Cappuzzo F, (2005) Role of gemcitabine in cancer therapy. Future Oncol 1: 7-17.
41. Crino L, Scagliotti GV, Ricci S, De Marinis F, Rinaldi M, et al. (1999) Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 17: 3522-3530.
42. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, et al. (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18: 3068-3077.
43. Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, et al. (1995) Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 13: 2731-2736.
44. Lorusso D, Di Stefano A, Fanfani F, Scambia G, (2006) Role of gemcitabine in ovarian cancer treatment. Ann Oncol 17Suppl 5: v188-194.
45. Matsuo K, Lin YG, Roman LD, Sood AK, (2010) Overcoming platinum resistance in ovarian carcinoma. Expert Opin Investig Drugs 19: 1339-1354.
46. Suprasert P, Cheewakriangkrai C, Manopunya M, (2012) Outcome of single agent generic gemcitabine in platinum- resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma. Asian Pac J Cancer Prev 13: 517-520.
47. Olinici CD, (1971) Double minute chromatin bodies in a case of ovarian ascitic carcinoma. Br J Cancer 25: 350-353.
48. Woods LK, Morgan RT, Quinn LA, Moore GE, Semple TU, et al. (1979) Comparison of four new cell lines from patients with adenocarcinoma of the ovary. Cancer Res 39: 4449-4459.
49. Atkin NB, Baker MC, Ferti-Passantonopoulou A, (1983) Chromosome changes in early gynecologic malignancies. Acta Cytol 27: 450-453.
50. Tanaka K, Boice CR, Testa JR, (1989) Chromosome aberrations in nine patients with ovarian cancer. Cancer Genet Cytogenet 43: 1-14.
51. McGill JR, Beitzel BF, Nielsen JL, Walsh JT, Drabek SM, et al. (1993) Double minutes are frequently found in ovarian carcinomas. Cancer Genet Cytogenet 71: 125-131.
52. Raymond E, Faivre S, Weiss G, McGill J, Davidson K, et al. (2001) Effects of hydroxyurea on extrachromosomal DNA in patients with advanced ovarian carcinomas. Clin Cancer Res 7: 1171-1180.
53. Donehower RC, (1992) An overview of the clinical experience with hydroxyurea. Semin Oncol 19: 11-19.
54. Xu B, Sun Z, Liu Z, Guo H, Liu Q, et al. (2011) Replication stress induces micronuclei comprising of aggregated DNA double-strand breaks. PLoS One 6: e18618.
55. Rao X, Zhang Y, Yi Q, Hou H, Xu B, et al. (2008) Multiple origins of spontaneously arising micronuclei in HeLa cells: direct evidence from long-term live cell imaging. Mutat Res 646: 41-49.
56. Massey AJ, Borgognoni J, Bentley C, Foloppe N, Fiumana A, et al. (2010) Context-dependent cell cycle checkpoint abrogation by a novel kinase inhibitor. PLoS One 5: e13123.
57. Schoenlein PV, Barrett JT, Kulharya A, Dohn MR, Sanchez A, et al. (2003) Radiation therapy depletes extrachromosomally amplified drug resistance genes and oncogenes from tumor cells via micronuclear capture of episomes and double minute chromosomes. Int J Radiat Oncol Biol Phys 55: 1051-1065.